Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 909-915

  Hamilton, Robert A ^a   Kane, Michael P ^a   Demers, Jason ^b  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; HYDRALAZINE; NIFEDIPINE; NITRENDIPINE; PLACEBO; VERAPAMIL;

ARITHMETIC; CLINICAL TRIAL; DATA ANALYSIS; DIABETIC NEPHROPATHY; DRUG EFFICACY; GEOMETRY; HUMAN; MEDICAL LITERATURE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; REVIEW; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; META-ANALYSIS; PROSPECTIVE STUDIES; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS;

EID: 0038720012     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.909.32726     Document Type: Review

References (50)

1. U.S. Renal Data System. USRDS 2001 annual data report. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, 2001.
2. Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice: nephropathy in patients with type 2 diabetes. N Engl J Med 2002;346:1145-51.
3. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2001;24:S71-3.
4. National Institutes of Health. Excerpts from the United States renal data system's 2001 annual data report: atlas of end-stage renal disease in the United States. Economic costs of end stage renal disease. Am J Kidney Dis 2001;38:S181-94.
5. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994;7:S84-92.
6. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.
7. Bakris GL. Renal effects of calcium antagonists in diabetes mellitus: an overview of studies in animal models and in humans. Am J Hypertens 1991;4:S487-93.
8. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998;54:889-96.
9. Anonymous. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
10. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
11. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2661;345:851-60.
12. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
13. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2002;25:S85-9.
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993;329:1456-62.
15. Cooper ME. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens Suppl 1996;14:S11-4.
16. Mogensen CE. Preventing end-stage renal disease. Diabet Med 1998;15(suppl 4):S51-6.
17. Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 1996;10:133-5.
18. Rodby RA. Type II diabetic nephropathy: its clinical course and therapeutic implications. Semin Nephrol 1997;17:132-47.
19. Ruilope LM. Effects of angiotensin converting enzyme inhibitors on the progression of diabetic nephropathy. J Hypertens Suppl 1995;13:S91-3.
20. Ruggenenti P, Remuzzi G. The renoprotective action of angiotensin-converting enzyme inhibitors in diabetes. Exp Nephrol 1996;4(suppl 1):53-60.
21. McClave JT, Dietrich FH. Statistics, 6th ed. New York: Maxwell Macmillan International, 1994:967.
22. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine, 2nd ed. Monographs in epidemiology and biostatistics. New York: Oxford University Press, 2000:306.
23. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-9.
24. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
25. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:1641-50.
26. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-9.
27. Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992;19:11237-42.
28. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995;69:41-8.
29. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994;43:1108-13.
30. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria: a randomized cross-over study. Nephron 1998;80:175-82.
31. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1998;128:982-8.
32. Romero R, Salinas I, Lucas A, et al. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care 1993;16:597-600.
33. Sano T, Hotta N, Kawamura T, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in normotensive type 2 diabetic patients: results of a 4-year, prospective, randomized study. Diabet Med 1996;13:120-4.
34. Stornello M, Valvo EV, Scapellato L. Angiotensin converting enzyme inhibition in normotensive type II diabetics with persistent mild proteinuria. J Hypertens Suppl 1989;7:S314-5.
35. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996;45:216-22.
36. Lebovitz HE, Wiegmann TB, Cnaan A, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994;45:S150-5.
37. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000;23:1278-83.
38. Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US [letter]. Diabetes Care 2001;24:412.
39. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third national health and nutrition examination survey, 1988-1994. Diabetes Care 1998;21:518-24.
40. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985;313:1617-20.
41. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.
42. Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989;36:526-36.
43. Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 1986;293:471-4.
44. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001;345:910-2.
45. Jafar TH, Stark PC, Schmid CH, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-40.
46. Parving HH, Chaturvedi N, Viberti G, Mogensen CE. Does microalbuminuria predict diabetic nephropathy? Diabetes Care 2002;25:406-7.
47. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7.
48. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Diabetic nephropathy. Diabetes Care 2003;26(suppl 1):S94-8.
49. Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26(suppl 1):S80-2.
50. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.